SIRT3 silencing could produce an increment in ROS production and compromise the antioxidant response, thus, producing an enhancement of cisplatin-triggered apoptosis, which sensitizes breast cancer cells to cisplatin treatments (110). This evidence concerns the gene SIRT3 and breast cancer.